These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 3678124

  • 1. [Characteristics of anthracycline-resistant strains of P388 leukemia].
    Goncharova SA, Demidova NS, Shiriaeva OA, Shevtsova VN, Konovalova NP.
    Eksp Onkol; 1987; 9(4):42-7. PubMed ID: 3678124
    [Abstract] [Full Text] [Related]

  • 2. [Sensitivity to chemotherapeutic preparations of anthracycline-resistant strains of murine leukemia P388].
    Demidova NS, Goncharova SA, Shiriaeva OA, Konovalova NP.
    Eksp Onkol; 1989; 11(1):65-8. PubMed ID: 2924713
    [Abstract] [Full Text] [Related]

  • 3. [Gene amplification in murine leukemia cells with multiple drug resistance acquired in vivo].
    Demidova NS, Goncharova SA, Chernova OB, Kopnin BP, Gudkov AV.
    Genetika; 1987 Oct; 23(10):1797-806. PubMed ID: 3692152
    [Abstract] [Full Text] [Related]

  • 4. [Phosphorus-containing metabolites in the cells of anthracycline-resistant strains of leukemia P388].
    Shiriaeva OA, Semenova NA, Sibel'dina LA, Goncharova SA, Konovalova NP.
    Eksp Onkol; 1989 Oct; 11(4):70-3. PubMed ID: 2759015
    [Abstract] [Full Text] [Related]

  • 5. Phosphorus-containing metabolites in anthracycline-resistant murine leukemia P388 cells.
    Shiryaeva OA, Semenova NA, Sibeldina LA, Goncharova SA, Konovalova NP.
    Neoplasma; 1992 Oct; 39(4):229-32. PubMed ID: 1436233
    [Abstract] [Full Text] [Related]

  • 6. [Role of intracellular pH in the development of resistance of leukemic cells to antineoplastic drugs].
    Shestova OL, Ogloblina TA, Litinskaia LL.
    Eksp Onkol; 1990 Oct; 12(3):61-2. PubMed ID: 2344828
    [Abstract] [Full Text] [Related]

  • 7. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
    Inaba M, Nagashima K.
    Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
    [Abstract] [Full Text] [Related]

  • 8. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.
    Kessel D, Wilberding C.
    Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944
    [Abstract] [Full Text] [Related]

  • 9. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
    Lepri E, Menconi E, Barzi AM.
    Boll Soc Ital Biol Sper; 1984 Jul 31; 60(7):1369-75. PubMed ID: 6477749
    [Abstract] [Full Text] [Related]

  • 10. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
    Ramu A, Fuks Z, Gatt S, Glaubiger D.
    Cancer Res; 1984 Jan 31; 44(1):144-8. PubMed ID: 6690032
    [Abstract] [Full Text] [Related]

  • 11. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK, Chitnis MP, Embrey WM, Gregory EB.
    Cancer Treat Rep; 1978 Oct 31; 62(10):1535-47. PubMed ID: 709555
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effect of selected daunorubicin derivatives in mice with P 388 leukemia.
    Kuśnierczyk H, Rak J, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1986 Oct 31; 34(3):259-62. PubMed ID: 3592929
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T, Oh-Hara T, Sudo Y, Naito M.
    Anticancer Res; 1993 Oct 31; 13(2):357-61. PubMed ID: 8517647
    [Abstract] [Full Text] [Related]

  • 14. [Cytostatic action of N-ethyl-13-dihydrorubomycin on the cells of various tumor strains].
    Volkolupova OP.
    Antibiotiki; 1984 Jun 31; 29(6):435-7. PubMed ID: 6548103
    [Abstract] [Full Text] [Related]

  • 15. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ, Wang H, Blair GW.
    Cancer Res; 1986 Jun 31; 46(6):2978-83. PubMed ID: 3698020
    [Abstract] [Full Text] [Related]

  • 16. Flow cytometric screening for selective toxicity to multidrug-resistant cells.
    Frankfurt OS.
    J Natl Cancer Inst; 1987 Oct 31; 79(4):831-6. PubMed ID: 3477663
    [Abstract] [Full Text] [Related]

  • 17. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.
    Inaba M, Johnson RK.
    Cancer Res; 1977 Dec 31; 37(12):4629-34. PubMed ID: 922743
    [Abstract] [Full Text] [Related]

  • 18. Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D.
    Wilkoff LJ, Dulmadge EA.
    J Natl Cancer Inst; 1978 Dec 31; 61(6):1521-4. PubMed ID: 281559
    [Abstract] [Full Text] [Related]

  • 19. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M.
    Anticancer Res; 1994 Dec 31; 14(5A):1995-2003. PubMed ID: 7847840
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.
    Ramu A, Shan TC, Glaubiger D.
    Cancer Treat Rep; 1983 Oct 31; 67(10):895-9. PubMed ID: 6354437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.